There are currently 2688 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center and Brigham and Women's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Oxytocin for Weight Loss in Adolescents
NCT04551482
Recruiting
This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin in youths with obesity, ages 12-18 years old. Subjects will be randomized to receive intranasal oxytocin or placebo (1 spray per nostril, 4 times per day) for 12 weeks. Study visits include screening to determine eligibility, 2-part main study visits at baseline, week 8, and week 12, and safety check-in visits at weeks 1, and 4; phone calls at weeks 2, 6, and 10, with a safety follow-up visit 6 wee... Read More
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
05/14/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Obesity, Adolescent, Oxytocin
Register for Updates
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06801236
Recruiting
This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Harvard Medical School-Massachusetts General Hospital, Boston, Massachusetts
Conditions: Prostate Cancer (Adenocarcinoma), MCRPC (metastatic Castration-resistant Prostate Cancer)
Register for Updates
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
NCT05473910
Recruiting
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor, MMUD, or MUD
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Mass General Hospital, Boston, Massachusetts
Conditions: AML, Myelodysplastic Syndromes, ALL, Adult
Register for Updates
Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck
NCT06744296
Recruiting
This study will test the ability of a personalized blood test to determine which head and neck cancer patients will have a recurrence after treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Massachusetts Eye and Ear, Boston, Massachusetts
Conditions: Squamous Cell Carcinoma of Head and Neck
Register for Updates
Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study)
NCT06584942
Recruiting
The goal of this study is to observe the impact of suvorexant, sold as BELSOMRA, on brain activity of people who frequently use cannabis. Suvorexant is an FDA-approved medication to treat insomnia. Researchers think that suvorexant may reduce activity in certain parts of the brain associated with cannabis use. Researchers are studying if this medication does affect brain activity in these areas. For this study, participants will be asked to complete four study visits over approximately 14 days.... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
05/14/2025
Locations: Center for Addiction Medicine, Massachusetts General Hospital, Boston, Massachusetts
Conditions: Cue-reactivity, Cannabis Use Disorder, Functional MRI, Orexin Antagonist
Register for Updates
Integrating Pain-CBT Into an mHealth Analgesic Support Intervention for Patients With Chronic Pain From Advanced Cancers
NCT06722014
Recruiting
Smartphone Technology to Alleviate Malignant Pain (STAMP) + Cognitive Behavioral Therapy for Pain (STAMP+CBT) The purpose of the study is to develop and refine the mHealth pain-CBT app intervention and carry out a randomized pilot to test the novel mHealth (Mobile health technology) intervention, which harmonizes psychological and pharmacological support for advanced cancer pain. The name of the study smartphone application involved in this study is: -STAMP+CBT
Gender:
ALL
Ages:
22 years and above
Trial Updated:
05/14/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Pain, Pain Syndrome, Advanced Cancer
Register for Updates
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis
NCT05327127
Recruiting
A study to investigate the use of combination therapy with two investigational products for the treatment of adult patients with Nonalcoholic steatohepatitis (NASH).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Boston Medical Center Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts
Conditions: NASH
Register for Updates
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
NCT05911763
Recruiting
This is a prospective, observational, multi-center longitudinal cohort study to describe the real-world effectiveness, safety and treatment usage of efanesoctocog alfa in patients with hemophilia A treated per standard of care in the US and Japan. Patients will be enrolled in the study after the introduction of efanesoctocog alfa in the hemophilia treatment landscape in each study country. Decision to initiate treatment with commercially available efanesoctocog alfa will be made by the treating... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/13/2025
Locations: Massachusetts General Hospital- Site Number : 8400017, Boston, Massachusetts +1 locations
Conditions: Hemophilia A
Register for Updates
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
NCT06369155
Recruiting
This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma. The name of the study drug involved in this study is: -Azenosertib (a type of Wee1 inhibitor)
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Uterine Serous Carcinoma, Uterine Carcinoma, Uterine Cancer
Register for Updates
A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity
NCT06854952
Recruiting
This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/13/2025
Locations: FALCON Research Site, Boston, Massachusetts
Conditions: Overweight or Obesity
Register for Updates
Positive Minds Strong Joints for Knee Osteoarthritis
NCT06493903
Recruiting
The aim of this research study is to test the feasibility of a physical and mental health intervention (Positive Minds, Strong Joints or PMSJ) for Black adults with knee osteoarthritis (OA).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/13/2025
Locations: Boston University, Boston, Massachusetts
Conditions: Osteoarthritis, Knee
Register for Updates
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
NCT04790370
Recruiting
There are many available treatments for pulmonary embolism (PE), but the best treatment for this condition is not known. The HI-PEITHO study will compare two treatment options that are both available on the market for the treatment of PE. Patients will be randomized 1:1 to receive either blood thinners (anticoagulation) or blood thinners (anticoagulation) in combination with a device called the EkoSonicTM Endovascular device to dissolve blood clots. Patients will be followed for 12 months after... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/13/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Pulmonary Embolism
Register for Updates